DALLAS, Texas – Baylor Scott & White Research Institute announces a collaboration with Exact Sciences Corp.
The organizations will establish the Texas Multi-Cancer Early Detection Registry with the aim of intercepting more cancers in Texans earlier, when treatment is more effective.
As part of the program, healthcare providers at Baylor Scott & White will administer approximately 50,000 Multi-Cancer Early Detection tests to patients from diverse racial, social and geographic backgrounds, including urban and rural areas, alongside standard-of-care screenings across North and Central Texas during the next three years.
“With this collaboration, we aim to disrupt the timeline of cancer detection giving patients the power to live well by earlier detection and treatment of cancer,” said Ronan Kelly, MD, director of oncology, Baylor Scott & White Charles A. Sammons Cancer Center at Baylor University Medical Center at Dallas and chief of oncology, North Texas Division, Baylor Scott & White Health. “It is essential to have a wide range of people from different communities participating in order to reduce biases, enable health equity and produce more innovative science.”
The program will utilize Exact Sciences’ Multi-Cancer Early Detection test to complement standard screening methods and aid in early-stage cancer detection. Early detection is associated with higher rates of survival and positive patient outcomes.
The program will generate much-needed real world evidence that the teams will use to assess:
- Efficiency of pathways created for diagnostic resolution for patients and providers.
- Clinical test implementation by a broad array of healthcare providers.
- Resonant test messaging across a diverse group of patients.
“As the largest not-for-profit integrated healthcare delivery network in the State of Texas, and one of the largest in the country, our health system is uniquely poised to play a significant role in the U.S. government’s Cancer Moonshot initiative with the aim of decreasing cancer mortality by 50% over the next 25 years. The way we will achieve these goals is by early detection and early treatment,” said Dr. Kelly. “We are excited to add this project among our many initiatives to improve cancer interception across Texas. We are eager to begin this work with Exact Sciences to help close gaps in existing cancer screening programs.”
About Baylor Scott & White Health
As the largest not-for-profit health system in the state of Texas, Baylor Scott & White promotes the health and well-being of every individual, family and community it serves. It is committed to making quality care more accessible, convenient and affordable through its integrated delivery network, which includes the Baylor Scott & White Health Plan, Baylor Scott & White Research Institute, the Baylor Scott & White Quality Alliance and its leading digital health platform – MyBSWHealth. Through 51 hospitals and more than 1,200 access points, including flagship academic medical centers in Dallas, Fort Worth and Temple, the system offers the full continuum of care, from primary to award-winning specialty care. Founded as a Christian ministry of healing more than a century ago, Baylor Scott & White today serves more than three million Texans. For more information, visit BSWHealth.com.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
Oncotype is a registered trademark of Genomic Health, Inc. Exact Sciences and Cologuard are registered trademarks of Exact Sciences Corporation. All other trademarks and service marks are the property of their respective owners.
# # #
